Factors Associated With Elevated N-Terminal Pro B-Type Natriuretic Peptide Concentrations at the Convalescent Stage and 1-Year Outcomes in Patients With Heart Failure With Preserved Ejection Fraction-Reference-Cited by-同舟云学术

Factors Associated With Elevated N-Terminal Pro B-Type Natriuretic Peptide Concentrations at the Convalescent Stage and 1-Year Outcomes in Patients With Heart Failure With Preserved Ejection Fraction

Published:2020-08-07 Issue:8 Volume:2 Page:400-408
ISSN:2434-0790
Container-title:Circulation Reports
language:en
Short-container-title:Circ Rep

Author:

Oeun Bolrathanak¹,Nakatani Daisaku¹,Hikoso Shungo¹,Kojima Takayuki¹,Dohi Tomoharu¹,Kitamura Tetsuhisa²,Okada Katsuki¹,Sunaga Akihiro¹,Kida Hirota¹,Yamada Takahisa³,Uematsu Masaaki⁴,Yasumura Yoshio⁵,Higuchi Yoshiharu⁶,Mano Toshiaki⁷,Nagai Yoshiyuki⁸,Fuji Hisakazu⁹,Mizuno Hiroya¹,Sakata Yasushi¹,

Affiliation:

1. Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

2. Department of Environmental Medicine and Population Sciences, Osaka University Graduate School of Medicine

3. Division of Cardiology, Osaka General Medical Center

4. Division of Cardiology, National Hospital Organization, Osaka National Hospital

5. Division of Cardiology, Amagasaki Chuo Hospital

6. Division of Cardiology, Osaka Police Hospital

7. Division of Cardiology, Kansai Rosai Hospital

8. Division of Cardiology, Rinku General Medical Center

9. Division of Cardiology, Kobe Ekisaikai Hospital

Publisher

Japanese Circulation Society

Subject

Marketing,Organizational Behavior and Human Resource Management,Strategy and Management,Drug Discovery,Pharmaceutical Science,Pharmacology

Link

https://www.jstage.jst.go.jp/article/circrep/2/8/2_CR-20-0051/_pdf

Reference32 articles.

1. 1. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6: 257–260.

2. 2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137–e161.

3. 3. Andersson C, Vasan RS. Epidemiology of heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10: 377–388.

4. 4. Tribouilloy C, Rusinaru D, Mahjoub H, Soulière V, Lévy F, Peltier M, et al. Prognosis of heart failure with preserved ejection fraction: A 5 year prospective population-based study. Eur Heart J 2008; 29: 339–347.

5. 5. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260–269.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The prognostic value of systemic vascular resistance in heart failure patients with permanent atrial fibrillation: a retrospective study;Heart and Vessels;2023-09-25

2. Clinical trajectories and outcomes of patients with heart failure with preserved ejection fraction with normal or indeterminate diastolic function;Clinical Research in Cardiology;2022-11-10

3. Albumin-to-globulin ratio predicts clinical outcomes of heart failure with preserved ejection fraction in women;Heart and Vessels;2022-05-21

4. Prognosticators of All-Cause Mortality in Patients With Heart Failure With Preserved Ejection Fraction;The American Journal of Cardiology;2021-11